Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the availability of high-efficacy treatments for relapsing-remitting MS on the NHS.

The National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether new medicines should be routinely funded by the NHS based on an assessment of their costs and benefits. The NHS in England is legally required to fund medicines recommended by NICE, which has recommended a number of new medicines for use in the treatment of relapsing-remitting multiple sclerosis (MS) that are now routinely available for use in the treatment of NHS patients.

Most recently, in April 2025, NICE recommended cladribine for treating active relapsing-remitting forms of MS. In December 2024, NICE had already recommended ublituximab for treating relapsing-remitting MS.